Related references
Note: Only part of the references are listed.
Article
Cardiac & Cardiovascular Systems
Federico Guerra et al.
Summary: The HeartLogic algorithm combines data from multiple implantable defibrillators (ICD)-based sensors to predict impending heart failure (HF) decompensation. This study implemented the algorithm for remote monitoring of HF patients and evaluated the approach to diuretic dosing and timing of intervention in patients with device alerts. The results showed that the use of decongestive treatment adjustments triggered by alerts seemed safe and effective, with early use of decongestive treatment and higher dosages of diuretics associated with more favorable outcomes.
CLINICAL CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Adrian F. Hernandez et al.
Summary: The clinical integration and safety of the HeartLogic multisensor index and alerts in heart failure (HF) care were evaluated. The study found that alert cases prompted augmentation of HF medications and were associated with faster recovery of the HeartLogic Index. Although there were a few serious adverse events related to alert-prompted medication change, the overall implementation of HeartLogic alert management was deemed safe in HF care. The levels of NTproBNP significantly decreased during the treatment process.
JOURNAL OF CARDIAC FAILURE
(2022)
Review
Cardiac & Cardiovascular Systems
Giuseppe Boriani et al.
Summary: Effective drug and device therapy can reduce the occurrence of heart failure worsening and SCD in heart failure patients, with the added benefit of positive cardiac remodeling.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Leonardo Calo et al.
Summary: The HeartLogic algorithm effectively identifies patients at increased risk of heart failure events and lower rate of heart failure events is observed when clinical actions are taken in response to alerts. Extra in-office visits do not seem to be necessary for managing HeartLogic alerts effectively.
CIRCULATION-HEART FAILURE
(2021)
Article
Pharmacology & Pharmacy
Federico Guerra et al.
Summary: Sacubitril/valsartan improves systolic function in HFrEF, mainly due to reverse left ventricular remodelling. Improvement in EF after 6 months of treatment could help prevent ICD implantation in nearly one out of four patients, with important clinical and economic implications. However, the risk of sudden cardiac death in this recovered HFrEF population has not been thoroughly studied, and the present data should be interpreted only as hypothesis-generating.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Roy S. Gardner et al.
Summary: This study compared the patterns of implantable device-based sensor measurements in patients with COVID-19, heart failure, and pneumonia, and found that COVID-19 patients showed early and significant increases in respiratory rate and temperature compared to those with heart failure or pneumonia. Additionally, activity levels decreased more in COVID-19 patients, while there were no significant changes in heart sounds among COVID-19 and pneumonia patients compared to the known changes in heart failure decompensation.
Article
Cardiac & Cardiovascular Systems
John P. Boehmer et al.
JACC-HEART FAILURE
(2017)
